SCHEMBL753289

SCHEMBL753289

CC(C)(C)c1c(N)ccc(C(=O)O)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.46
KDM4E B2RXH2 7/20 0.42
ALDH1A1 P00352 6/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 4/20 0.40
GFER P55789 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TDP1 Q9NUW8 5/20 0.39
MAPT P10636 4/20 0.39
MEN1 O00255 3/20 0.39
THRB P10828 2/20 0.39
USP2 O75604 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
APEX1 P27695 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
MCL1 Q07820 1/20 0.39
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16634634 0.86 KEAP1 (0.46) KEAP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7500765 0.84 KDM4E (0.51) KEAP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL18113432 0.81 ALDH1A1 (0.49) KEAP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL17374983 0.80 CSNK2A1 (0.44) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL4853079 0.80 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL600522 0.77 KEAP1 (0.55) KEAP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1901160 0.76 KDM4E (0.43) KEAP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL239744 0.76 ALDH1A1 (0.32) ALDH1A1KMT2AMAPTMEN1PKM
SCHEMBL17374953 0.76 TDP1 (0.47) KDM4EALDH1A1HPGDHSD17B10TDP1
SCHEMBL28716238 0.76 GABRP (0.42) KEAP1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297207-B2 Maytansinoid derivatives, conjugates thereof, and methods of use REGENERON PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-20220259225-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use REGENERON PHARMACEUTICALS, INC. 2022-08-18 US disclosed
US-20200385402-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use REGENERON PHARMACEUTICALS, INC. 2020-12-10 US disclosed
EP-3273998-B1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMA (US) 2019-09-04 EP disclosed
EP-3273998-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE Regeneron Pharmaceuticals, Inc. (US) 2018-01-31 EP disclosed
US-20160375147-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMACEUTICALS, INC. 2016-12-29 US disclosed
WO-2016160615-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMACEUTICALS, INC. (US) 2016-10-06 WO disclosed
EP-1996563-B1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2012-03-21 EP disclosed
US-7002020-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY (US) 2006-02-21 US disclosed
US-20050004174-A1 Antibacterial agents GORDEEV MIKHAIL F (US) 2005-01-06 US disclosed
US-20020183371-A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation GORDEEV MIKHAIL F (US) 2002-12-05 US disclosed
US-20020169191-A1 Oxazolidinone compounds and methods of preparation and use thereof PHARMACIA & UPJOHN COMPANY (US) 2002-11-14 US disclosed
US-6441005-B1 BACTERICIDES, ANTIBIOTICS AND MICROBIOCIDES PHARMACIA & UPJOHN COMPANY 2002-08-27 US disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 US disclosed
EP-1049682-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION Versicor, Inc. (US) 2000-11-08 EP disclosed
EP-0773930-B1 AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS ZENECA LTD (GB) 2000-10-11 EP disclosed
WO-1999037630-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION VERSICOR, INC. (US) 1999-07-29 WO disclosed
US-5843942-A Aromatic amino ethers as pain relieving agents ZENECA LIMITED (GB) 1998-12-01 US disclosed
US-5395838-A Aromatic aminomethyl substitutes compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-03-07 US disclosed
US-5089499-A Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160375147-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE SLC10A1, HNMT, OGFR KEAP1 968/4885KDM4E 4593/4885ALDH1A1 317/4885
US-20020183371-A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PAICS, CDK4, OXA1L KEAP1 2798/4885KDM4E 1239/4885ALDH1A1 1371/4885
US-20200385402-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use SLC10A1, HNMT, OGFR KEAP1 968/4885KDM4E 4593/4885ALDH1A1 317/4885
US-12297207-B2 Maytansinoid derivatives, conjugates thereof, and methods of use SLC10A1, HNMT, OGFR KEAP1 968/4885KDM4E 4593/4885ALDH1A1 317/4885
US-20020169191-A1 Oxazolidinone compounds and methods of preparation and use thereof OXA1L, PAM, DPM1 KEAP1 3356/4885KDM4E 1137/4885ALDH1A1 558/4885
US-20050004174-A1 Antibacterial agents PAICS, OXA1L, PNKP KEAP1 1889/4885KDM4E 996/4885ALDH1A1 1632/4885
US-20220259225-A1 Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use SLC10A1, HNMT, OGFR KEAP1 968/4885KDM4E 4593/4885ALDH1A1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.